AP1189

Phase 2Small molecule

SSynAct Pharma Aps

AP1189 is one of 44 small molecule programs targeting Proteinuria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProteinuriaRecruiting

Rheumatoid ArthritisCompleted

ProteinuriaPhase 2

Recruiting

Rheumatoid ArthritisPhase 2

Completed

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actos

Takeda

Preclinical

2 2

Celexa

AbbVie

Preclinical

1 3

Voltaren

Cataflam

Plaquenil

AP1189

3 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Completed·SSynAct Pharma Aps·Phase 2·NCT05604885·125 enrolled

A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

Completed·SSynAct Pharma Aps·Phase 2·NCT05516979·127 enrolled

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

Recruiting·SSynAct Pharma Aps·Phase 2·NCT06671054·240 enrolled

Proteinuria1 trial

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Recruiting·SSynAct Pharma Aps·Phase 2·NCT04456816·23 enrolled

Joint Disease1 trial

A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease

Completed·SSynAct Pharma Aps·Phase 2·NCT04004429·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AP1189. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AP1189 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AP1189. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SynAct Pharma Aps company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSynAct Pharma Aps

AP1189

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Proteinuria1 trial

Joint Disease1 trial

References

Drug Info

Quick Facts

Related News